Skip to search formSkip to main contentSkip to account menu

MK-7965

Known as: CDK inhibitor SCH 727965 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Neuroblastoma (NB), the most common extracranial solid tumor of childhood, is responsible for approximately 15% of cancer-related… 
2015
2015
KRAS is activated by mutation in the vast majority of cases of pancreatic cancer; unfortunately, therapeutic attempts to inhibit… 
Review
2014
Review
2014
Introduction: Cyclin-dependent kinases (CDK) represent attractive targets in oncology due to their key role in controlling gene… 
2013
2013
Objectives: Dinaciclib (MK-7965, formerly SCH 727965), a novel, small-molecule inhibitor of cyclindependent kinases, has been… 
Highly Cited
2012
Highly Cited
2012
  • Malini Guha
  • Nature Reviews Drug Discovery
  • 2012
  • Corpus ID: 34625364
After more than a decade of clinical development for cancer and numerous failures, Phase III trials of cyclin-dependent kinase…